Effectiveness and Safety of Edaravone Dexborneol in Acute Ischemic Stroke

Launched by XUANWU HOSPITAL, BEIJING · Nov 30, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a medication called edaravone dexborneol to see how effective and safe it is for patients with acute ischemic stroke, which happens when blood flow to the brain is blocked. The trial is taking place at multiple locations and aims to gather real-world data on how this treatment works for people experiencing this kind of stroke.

To participate, individuals must be at least 18 years old and have been diagnosed with an acute ischemic stroke within the last 14 days. They should have been in good health before the stroke and must agree to take part in the study after being informed about it. Unfortunately, some people may not qualify, including those with certain types of bleeding in the brain or severe health issues. Participants can expect close monitoring and regular check-ins to assess their health and the effects of the treatment during the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age≥18 years old；
• • Clinically diagnosed as acute ischemic stroke；
• • Time from symptom onset to admission≤14 days (symptom onset time is defined as last known well time)；
• • Pre-stroke mRS ≤1；
• • Have been informed of the content of the informed consent form and agree to participate.
• Exclusion Criteria:
• • Acute intracranial hemorrhagic diseases confirmed by images: parenchymal hemorrhage, epidural hematoma, subdural hematoma, ventricular hemorrhage, subarachnoid hemorrhage, etc.
• • Patients who are pregnant or lactating and who are planned to become pregnant within 90 days;
• • Patients with severe renal failure (eGFR\<30ml/min);
• • Patients with concurrent malignancy or severe systemic disease with an estimated survival of less than 90 days;
• • Patients with severe mental disorders or unable to complete the informed consent and follow-up due to dementia;
• • Patients who are judged unsuitable for participation in the study.